Increasing evidence suggests that the severe gum disease, periodontitis, may contribute to central nervous system disorders ...

Just before the end of 2025, an oral version of a GLP-1 drug specifically used for weight management moved much closer to ...

The FDA has approved Wegovy (semaglutide) tablets, the first oral GLP-1 receptor agonist for the treatment of obesity.

Oral bacteria that migrate to the gut can generate metabolites that reach the brain and accelerate Parkinson’s disease.

High levels of the periodontal bacterium Fusobacterium nucleatum may be associated with more severe disability in people with multiple sclerosis.

The FDA has approved the first oral glucagon-like peptide-1 (GLP-1) receptor agonist for weight loss and to reduce the risk ...

The FDA approved the first oral GLP-1 for lowering body weight according to a press release from Novo Nordisk. Oral ...

A once-weekly oral combination of islatravir plus lenacapavir (Sunlenca) for HIV maintained similarly high rates of virologic ...

An oral formulation of semaglutide has received United States Food and Drug Administration approval for a new drug or biologic under the Prescription Drug User Fee Act. The University of Alabama at ...

Scientists are discovering that the oral microbiome—home to hundreds of species of bacteria and fungi—may help predict ...

Yesterday, the Food and Drug Administration (FDA) approved Novo Nordisk‘s (NYSE:NVO) Wegovy weight-loss pill, the first of its kind. This once-daily tablet uses the same active ingredient — ...

For this article, we wanted to clarify the role of an oral surgeon and when you might need our specialized care, as many ...